Trial Profile

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 IT or OAV101 IV in Clinical Trials

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Onasemnogene-abeparvovec (Primary) ; Onasemnogene-abeparvovec (Primary)
Indications Spinal muscular atrophy
Focus Adverse reactions
Acronyms SPECTRUM
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

10 Dec 2024 Planned number of patients changed from 260 to 175.
10 Dec 2024 Planned End Date changed from 18 Oct 2039 to 26 Jun 2030.
10 Dec 2024 Planned primary completion date changed from 18 Oct 2039 to 26 Jun 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com